Avoiding Coffee for Atrial Fibrillation
(DECAF Trial)

Recruiting in Palo Alto (17 mi)

Overseen byChris Wong, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of California, San Francisco

No Placebo Group

Trial Summary

What is the purpose of this trial?Given both the increasing population impact of atrial fibrillation (AF) and the widespread consumption of coffee in society, determining an associated benefit or risk of coffee consumption on AF is of great clinical relevance. This pilot study will evaluate the effect of randomly assigning participants undergoing electrical cardioversion to coffee abstinence or coffee consumption over a 6 month period. This pilot study will provide the first, randomized evaluation of coffee on AF outcomes and will provide important information on whether or not coffee has any effect on AF recurrence.

Eligibility Criteria

This trial is for men and women over 21 who have atrial fibrillation, drink coffee daily, and are scheduled for electrical cardioversion. They must be willing to either abstain from or continue drinking coffee and attend follow-up calls. Exclusions include allergies to coffee, recent heart surgeries, pregnancy plans within six months, or participation in conflicting studies.

Inclusion Criteria

I have ongoing atrial fibrillation.

I can attend all scheduled phone follow-ups.

I am 21 years old or older.

+5 more

Exclusion Criteria

Any other criteria, which would make the patient unsuitable to participate in this study as determined by the Principal Investigator (e.g., an uncontrolled drug and/or alcohol addiction)

I had a procedure to correct heart rhythm due to atrial flutter, not AF.

Current enrollment in an investigation or study of a cardiovascular device or investigational drug that would interfere with this study

+5 more

Participant Groups

The study tests the impact of coffee on atrial fibrillation by randomly assigning participants to two groups: one that avoids coffee and another that continues consumption post-electrical cardioversion. The goal is to see if avoiding or consuming coffee affects AF recurrence over a six-month period.

2Treatment groups

Experimental Treatment

Group I: ConsumeExperimental Treatment1 Intervention

Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.

Group II: AvoidExperimental Treatment1 Intervention

Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.